Table 1 Characteristics of the study sample (n = 28,729)
From: Quality use of medicines in patients with chronic kidney disease
Demographics | Number (%) |
|---|---|
Age (years) | |
20–29 | 6 (0.02) |
30–39 | 61 (0.21) |
40–49 | 257 (0.89) |
50–59 | 1039 (3.62) |
60–69 | 4234 (14.74) |
70–79 | 10,219 (35.57) |
80–89 | 10,434 (36.32) |
90+ | 2479 (8.63) |
Male Gender | 12,736 (44.3) |
CKD Risk Factors | |
Hypertension | 23,998 (83.2) |
CVD | 13,611 (47.4) |
Diabetes | 13,292 (46.3) |
Number of medications [Mean (SD)] | 8.42 (3.75) |
Top 5 medications categorised according to the ATC groups | |
Agents acting on the renin-angiotensin system | 20,391 (71.0) |
Analgesics | 16,084 (56.0) |
Drugs for acid-related disorders | 15,861 (55.2) |
Antithrombotic drugs | 11,691 (40.7) |
Diuretics | 10,965 (38.2) |
Stages of CKD | |
Stage 1 ≥ 90 mL/min/1.73m2 | 27 (0.1) |
Stage 2 60–89 mL/min/1.73m2 | 387 (6.8) |
Stage 3a 45–59 mL/min/1.73m2 | 18,553 (64.6) |
Stage 3b 30–44 mL/min/1.73m2 | 7539 (26.2) |
Stage 4 15–29 mL/min/1.73m2 | 1955 (6.8) |
Stage 5 < 15 mL/min/1.73m2 | 268 (0.9) |